Diabetic Medicine · 2000 · 82 citations · 8 references
MedicinePharmacologyPharmacotherapyNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDiabetes ManagementDiabetes MellitusPsychotic DisordersAntipsychotic Medication ManagementAtypical Antipsychotic TreatmentClozapine PharmacologyOlanzapine PharmacologyPsychosis PharmacotherapyPsychotic Disorders Diagnosis
AIMS: Atypical anti-psychotic drugs (APDs) are widely used in psychotic disorders refractory to conventional neuroleptic agents. RESULTS: Three cases of new-onset diabetes are reported in Caucasian men who were on clozapine (one) or olanzapine (two) for 3-6 months. They had a distinct presentation: weight loss, ketosis (one ketoacidosis), severe hyperglycaemia requiring insulin therapy, and relative insulin deficiency as reflected by glucagon stimulatory tests. In all cases, insulin was stopped within 1 month after the APD was discontinued. CONCLUSIONS: Novel APDs not only induce diabetes as a result of weight gain in predisposed patients, but can also lead to a reversible state of insulin deficiency, and sometimes ketoacidosis.
8
Clozapine for the Treatment-Resistant Schizophrenic
John M. Kane · Archives of General Psychiatry · 1988 · 4.1K citations
Medicine, Pharmacology, Psychiatry +16
Novel antipsychotics: comparison of weight gain liabilities.
Donna A. Wirshing, W C Wirshing, Lisa Kysar et al. · PubMed · 1999 · 527 citations
Novel antipsychotics and new onset diabetes
Donna A. Wirshing, Brad Spellberg, Stephen M. Erhart et al. · Biological Psychiatry · 1998 · 413 citations
Donna A. Wirshing, William C. Wirshing, Lisa Kysar et al. · The Journal of Clinical Psychiatry · 1999 · 396 citations
A historical perspective of clozapine.
Hanns Hippius · PubMed · 1999 · 165 citations